The purpose of the follow‐up study is to further explore the correlation between genomic characteristics and the efficacy of ALK‐TKI before and after treatment and to clarify the mechanism of resistance to ALK‐TKIs among Chinese patients with advanced ALK‐positive NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.